Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Roher AE, Kokjohn TA, Clarke SG, Sierks MR, Maarouf CL, Serrano GE, Sabbagh MS, Beach TG.

Neurochem Int. 2017 Nov;110:1-13. doi: 10.1016/j.neuint.2017.08.007. Epub 2017 Aug 12. Review.

2.

Chemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumab.

Roher AE, Maarouf CL, Kokjohn TA, Belden C, Serrano G, Sabbagh MS, Beach TG.

Am J Neurodegener Dis. 2016 Aug 26;5(4):158-170. eCollection 2016.

3.

Familial Presenilin Mutations and Sporadic Alzheimer's Disease Pathology: Is the Assumption of Biochemical Equivalence Justified?

Roher AE, Maarouf CL, Kokjohn TA.

J Alzheimers Dis. 2016;50(3):645-58. doi: 10.3233/JAD-150757. Review.

PMID:
26757189
4.

Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the γ-secretase inhibitor semagacestat.

Roher AE, Maarouf CL, Kokjohn TA, Whiteside CM, Kalback WM, Serrano G, Belden C, Liebsack C, Jacobson SA, Sabbagh MN, Beach TG.

Am J Neurodegener Dis. 2014 Dec 5;3(3):115-33. eCollection 2014.

5.

Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's disease.

Maarouf CL, Kokjohn TA, Walker DG, Whiteside CM, Kalback WM, Whetzel A, Sue LI, Serrano G, Jacobson SA, Sabbagh MN, Reiman EM, Beach TG, Roher AE.

PLoS One. 2014 Aug 28;9(8):e105784. doi: 10.1371/journal.pone.0105784. eCollection 2014.

6.

Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.

Roher AE, Maarouf CL, Malek-Ahmadi M, Wilson J, Kokjohn TA, Daugs ID, Whiteside CM, Kalback WM, Macias MP, Jacobson SA, Sabbagh MN, Ghetti B, Beach TG.

Am J Neurodegener Dis. 2013 Sep 18;2(3):187-207. eCollection 2013.

7.

Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy.

Roher AE, Cribbs DH, Kim RC, Maarouf CL, Whiteside CM, Kokjohn TA, Daugs ID, Head E, Liebsack C, Serrano G, Belden C, Sabbagh MN, Beach TG.

PLoS One. 2013;8(3):e59735. doi: 10.1371/journal.pone.0059735. Epub 2013 Mar 21.

8.

Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology.

Maarouf CL, Beach TG, Adler CH, Malek-Ahmadi M, Kokjohn TA, Dugger BN, Walker DG, Shill HA, Jacobson SA, Sabbagh MN, Roher AE; Arizona Parkinson’s Disease Consortium.

Biomark Insights. 2013;8:19-28. doi: 10.4137/BMI.S11422. Epub 2013 Mar 12.

9.

Molecular Differences and Similarities Between Alzheimer's Disease and the 5XFAD Transgenic Mouse Model of Amyloidosis.

Maarouf CL, Kokjohn TA, Whiteside CM, Macias MP, Kalback WM, Sabbagh MN, Beach TG, Vassar R, Roher AE.

Biochem Insights. 2013 Nov 21;6:1-10. doi: 10.4137/BCI.S13025. eCollection 2013.

10.

Neurochemical profile of dementia pugilistica.

Kokjohn TA, Maarouf CL, Daugs ID, Hunter JM, Whiteside CM, Malek-Ahmadi M, Rodriguez E, Kalback W, Jacobson SA, Sabbagh MN, Beach TG, Roher AE.

J Neurotrauma. 2013 Jun 1;30(11):981-97. doi: 10.1089/neu.2012.2699.

11.

Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations.

Castaño EM, Maarouf CL, Wu T, Leal MC, Whiteside CM, Lue LF, Kokjohn TA, Sabbagh MN, Beach TG, Roher AE.

Neurochem Int. 2013 Jan;62(2):145-56. doi: 10.1016/j.neuint.2012.12.001. Epub 2012 Dec 8.

12.

Cerebral blood flow in Alzheimer's disease.

Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze S, Belden C, Maarouf CL, Thiyyagura P, Mo H, Hunter JM, Kokjohn TA, Walker DG, Kruchowsky JC, Belohlavek M, Sabbagh MN, Beach TG.

Vasc Health Risk Manag. 2012;8:599-611. doi: 10.2147/VHRM.S34874. Epub 2012 Oct 23.

13.

Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects.

Maarouf CL, Beach TG, Adler CH, Shill HA, Sabbagh MN, Wu T, Walker DG, Kokjohn TA, Roher AE; Arizona PD Consortium.

Neurol Res. 2012 Sep;34(7):669-76. doi: 10.1179/1743132812Y.0000000063.

14.

Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease.

Hunter JM, Kwan J, Malek-Ahmadi M, Maarouf CL, Kokjohn TA, Belden C, Sabbagh MN, Beach TG, Roher AE.

PLoS One. 2012;7(5):e36893. doi: 10.1371/journal.pone.0036893. Epub 2012 May 16.

15.

Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging.

Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, Kruchowsky JC, Woltjer R, Kaye J, Castaño EM, Sabbagh MN, Beach TG, Roher AE.

PLoS One. 2011;6(11):e27291. doi: 10.1371/journal.pone.0027291. Epub 2011 Nov 7.

16.

Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?

Kokjohn TA, Maarouf CL, Roher AE.

Alzheimers Dement. 2012 Nov;8(6):574-83. doi: 10.1016/j.jalz.2011.05.2429. Epub 2011 Nov 2. Review.

17.

Biochemical and morphological characterization of the AβPP/PS/tau triple transgenic mouse model and its relevance to sporadic Alzheimer's disease.

Hunter JM, Bowers WJ, Maarouf CL, Mastrangelo MA, Daugs ID, Kokjohn TA, Kalback WM, Luehrs DC, Valla J, Beach TG, Roher AE.

J Alzheimers Dis. 2011;27(2):361-76. doi: 10.3233/JAD-2011-110608.

18.

Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets.

Kokjohn TA, Van Vickle GD, Maarouf CL, Kalback WM, Hunter JM, Daugs ID, Luehrs DC, Lopez J, Brune D, Sue LI, Beach TG, Castaño EM, Roher AE.

Biochim Biophys Acta. 2011 Nov;1812(11):1508-14. doi: 10.1016/j.bbadis.2011.07.004. Epub 2011 Jul 20.

19.

Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia.

Roher AE, Tyas SL, Maarouf CL, Daugs ID, Kokjohn TA, Emmerling MR, Garami Z, Belohlavek M, Sabbagh MN, Sue LI, Beach TG.

Alzheimers Dement. 2011 Jul;7(4):436-44. doi: 10.1016/j.jalz.2010.08.228. Epub 2011 Mar 9.

20.

Transcranial doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's disease.

Roher AE, Garami Z, Tyas SL, Maarouf CL, Kokjohn TA, Belohlavek M, Vedders LJ, Connor D, Sabbagh MN, Beach TG, Emmerling MR.

Alzheimers Dement. 2011 Jul;7(4):445-55. doi: 10.1016/j.jalz.2010.09.002. Epub 2011 Mar 9.

21.

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG.

J Alzheimers Dis. 2011;24(2):315-25. doi: 10.3233/JAD-2011-101809.

22.

The biochemical aftermath of anti-amyloid immunotherapy.

Maarouf CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC, Masliah E, Nicoll JA, Sabbagh MN, Beach TG, Castaño EM, Roher AE.

Mol Neurodegener. 2010 Oct 7;5:39. doi: 10.1186/1750-1326-5-39.

23.

Patients with Alzheimer disease have altered transmitral flow: echocardiographic analysis of the vortex formation time.

Belohlavek M, Jiamsripong P, Calleja AM, McMahon EM, Maarouf CL, Kokjohn TA, Chaffin TL, Vedders LJ, Garami Z, Beach TG, Sabbagh MN, Roher AE.

J Ultrasound Med. 2009 Nov;28(11):1493-500.

PMID:
19854964
24.

Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." Alzheimer's disease drugs: more than one barrier to breach.

Roher AE, Kokjohn TA.

Alzheimers Dement. 2009 Sep;5(5):437-8. doi: 10.1016/j.jalz.2009.07.037. No abstract available.

PMID:
19751925
25.

Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects.

Maarouf CL, Andacht TM, Kokjohn TA, Castaño EM, Sue LI, Beach TG, Roher AE.

Curr Alzheimer Res. 2009 Aug;6(4):399-406.

26.

Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions.

Kokjohn TA, Roher AE.

Alzheimers Dement. 2009 Jul;5(4):340-7. doi: 10.1016/j.jalz.2009.03.002. Review.

27.
28.

Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease.

Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN.

Alzheimers Dement. 2009 Jan;5(1):18-29. doi: 10.1016/j.jalz.2008.10.004.

29.

Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations.

Maarouf CL, Daugs ID, Spina S, Vidal R, Kokjohn TA, Patton RL, Kalback WM, Luehrs DC, Walker DG, Castaño EM, Beach TG, Ghetti B, Roher AE.

Mol Neurodegener. 2008 Nov 20;3:20. doi: 10.1186/1750-1326-3-20.

30.

Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy.

Van Vickle GD, Esh CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC, Walker DG, Lue LF, Beach TG, Davis J, Van Nostrand WE, Castaño EM, Roher AE.

Am J Pathol. 2008 Aug;173(2):483-93. doi: 10.2353/ajpath.2008.071191. Epub 2008 Jul 3.

31.

Presenilin-1 280Glu-->Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer's disease.

Van Vickle GD, Esh CL, Kokjohn TA, Patton RL, Kalback WM, Luehrs DC, Beach TG, Newel AJ, Lopera F, Ghetti B, Vidal R, Castaño EM, Roher AE.

Mol Med. 2008 Mar-Apr;14(3-4):184-94. doi: 10.2119/2007-00094.Van Vickle.

32.

TgCRND8 amyloid precursor protein transgenic mice exhibit an altered gamma-secretase processing and an aggressive, additive amyloid pathology subject to immunotherapeutic modulation.

Van Vickle GD, Esh CL, Kalback WM, Patton RL, Luehrs DC, Kokjohn TA, Fifield FG, Fraser PE, Westaway D, McLaurin J, Lopez J, Brune D, Newel AJ, Poston M, Beach TG, Roher AE.

Biochemistry. 2007 Sep 11;46(36):10317-27. Epub 2007 Aug 18.

PMID:
17705508
33.

Effects of Ultraviolet Radiation on the Gram-positive marine bacterium Microbacterium maritypicum.

Williams PD, Eichstadt SL, Kokjohn TA, Martin EL.

Curr Microbiol. 2007 Jul;55(1):1-7. Epub 2007 Jun 5.

PMID:
17551790
34.

Interaction of cardiovascular disease and neurodegeneration: transcranial Doppler ultrasonography and Alzheimer's disease.

Roher AE, Garami Z, Alexandrov AV, Kokjohn TA, Esh CL, Kalback WM, Vedders LJ, Wilson JR, Sabbagh MN, Beach TG.

Neurol Res. 2006 Sep;28(6):672-8.

PMID:
16945221
35.

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis.

Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Castaño EM, Roher AE.

Am J Pathol. 2006 Sep;169(3):1048-63.

36.

Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects.

Castaño EM, Roher AE, Esh CL, Kokjohn TA, Beach T.

Neurol Res. 2006 Mar;28(2):155-63.

PMID:
16551433
37.

An association with great implications: vascular pathology and Alzheimer disease.

Roher AE, Kokjohn TA, Beach TG.

Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):73-5. No abstract available.

PMID:
16493240
38.

Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.

Watson D, Castaño E, Kokjohn TA, Kuo YM, Lyubchenko Y, Pinsky D, Connolly ES Jr, Esh C, Luehrs DC, Stine WB, Rowse LM, Emmerling MR, Roher AE.

Neurol Res. 2005 Dec;27(8):869-81. Review.

PMID:
16354549
39.

Altered APP processing in PDAPP (Val717 --> Phe) transgenic mice yields extended-length Abeta peptides.

Esh C, Patton L, Kalback W, Kokjohn TA, Lopez J, Brune D, Newell AJ, Beach T, Schenk D, Games D, Paul S, Bales K, Ghetti B, Castaño EM, Roher AE.

Biochemistry. 2005 Oct 25;44(42):13807-19.

PMID:
16229470
40.

RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling.

Chaney MO, Stine WB, Kokjohn TA, Kuo YM, Esh C, Rahman A, Luehrs DC, Schmidt AM, Stern D, Yan SD, Roher AE.

Biochim Biophys Acta. 2005 Jun 30;1741(1-2):199-205. Epub 2005 Apr 19.

41.

The effects of salt concentration and growth phase on MRSA solar and germicidal ultraviolet radiation resistance.

Sheldon JL, Kokjohn TA, Martin EL.

Ostomy Wound Manage. 2005 Jan;51(1):36-8, 42-4, 46 passim. Review.

42.

Atherosclerosis of cerebral arteries in Alzheimer disease.

Roher AE, Esh C, Rahman A, Kokjohn TA, Beach TG.

Stroke. 2004 Nov;35(11 Suppl 1):2623-7. Epub 2004 Sep 16.

PMID:
15375298
43.

The human amyloid-beta precursor protein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates.

Roher AE, Kokjohn TA, Esh C, Weiss N, Childress J, Kalback W, Luehrs DC, Lopez J, Brune D, Kuo YM, Farlow M, Murrell J, Vidal R, Ghetti B.

J Biol Chem. 2004 Feb 13;279(7):5829-36. Epub 2003 Nov 26.

44.

Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease.

Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG.

Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2055-62. Epub 2003 Sep 25.

PMID:
14512367
45.

A beta, aging, and Alzheimer's disease: a tale, models, and hypotheses.

Chaney MO, Baudry J, Esh C, Childress J, Luehrs DC, Kokjohn TA, Roher AE.

Neurol Res. 2003 Sep;25(6):581-9. Review.

PMID:
14503011
46.

Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease.

Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, Luehrs DC, Childress JL, Beach TG, Weller RO, Kokjohn TA.

Mol Med. 2003 Mar-Apr;9(3-4):112-22.

47.

Of mice and men: The relevance of transgenic mice Abeta immunizations to Alzheimer's disease.

Roher AE, Kokjohn TA.

J Alzheimers Dis. 2002 Oct;4(5):431-4. No abstract available.

PMID:
12446974
48.

Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease.

Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D, Emmerling M, Goux W, Beach T.

Biochemistry. 2002 Sep 17;41(37):11080-90.

PMID:
12220172
49.

APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.

Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, Roher AE.

Biochemistry. 2002 Jan 22;41(3):922-8.

PMID:
11790115
50.

The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease.

Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, Kalback WM, Luehrs DC, Vishnivetskaya TA, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Weller RO, Roher AE.

Mol Med. 2001 Sep;7(9):609-18.

Supplemental Content

Loading ...
Support Center